amlexanox: the IKK-epsilon and TBK1 inhibitor explored in metabolic disease

amlexanox is a small-molecule benzopyranone with broad anti-inflammatory and anti-allergic activity. it has been FDA-approved since 1996 as an oral paste (Aphthasol) for the treatment of aphthous ulcers (canker sores). its inclusion in peptide-therapeutic conversations comes from a 2013 University of Michigan finding that the same molecule is a selective inhibitor of the non-canonical inflammatory kinases IKK-epsilon (IKKe) and TBK1, two pathways that are dysregulated in obesity and type 2 diabetes. the drug has since been repurposed in proof-of-concept clinical trials in obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD).

what is amlexanox?

amlexanox (2-amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid) is a small-molecule drug, not a peptide. it was originally developed by Takeda in Japan in the 1980s as an anti-allergic agent and was approved in the US in 1996 for treatment of aphthous ulcers under the brand name Aphthasol. it appears on this education site because of its modern repurposing in metabolic-disease research, where it sits in the same pipeline conversation as the GLP-1 incretin peptides.

the molecule is a benzopyranone (a chromenopyridine) with a known mast-cell stabilizing and anti-inflammatory profile. those original properties are the basis for the aphthous ulcer indication and for an additional historical Japanese use as an inhaled anti-asthmatic in some formulations [1]. the 1996 Aphthasol approval was based on small randomized trials showing faster healing and pain reduction in recurrent aphthous ulcers, and the oral paste remained the only approved formulation for many years.

what changed amlexanox's relevance for metabolic disease was the 2013 paper by Reilly and colleagues at the University of Michigan, which used a screen for selective IKKe and TBK1 inhibitors and identified amlexanox as a hit [2]. IKKe and TBK1 are non-canonical inflammatory kinases that are upregulated in adipose tissue and liver in obese mice, and the Michigan group hypothesized that inhibiting them would reverse a metabolic-inflammation block on energy expenditure.

how does it work in metabolic disease?

amlexanox selectively inhibits IKK-epsilon (IKKe) and TBK1, two related serine/threonine kinases that sit downstream of obesity-associated inflammation in adipose tissue and liver. inhibition restores the cyclic AMP signaling that obesity has blunted, increases energy expenditure, improves insulin sensitivity, and reduces hepatic steatosis in rodent models.

the mechanistic story laid out by the Michigan group is specific. obesity drives chronic low-grade inflammation that activates IKKe and TBK1 in adipocytes and hepatocytes. IKKe and TBK1 in turn phosphorylate and inactivate phosphodiesterase 3B (PDE3B), which then over-degrades cAMP. lower cAMP means reduced PKA signaling, reduced lipolysis, and reduced thermogenesis. amlexanox breaks this loop by selectively inhibiting IKKe and TBK1, restoring cAMP, and unlocking the energy-expenditure response that obesity had suppressed [2].

in diet-induced obese mice, oral amlexanox produced significant weight loss without reducing food intake, improved glucose tolerance and insulin sensitivity, reduced hepatic steatosis, and reduced markers of adipose-tissue inflammation. the food-intake-independent weight loss is mechanistically distinct from the appetite-suppressing GLP-1 agonists, which is the basis for the proposal that amlexanox could complement rather than replace incretin therapy [3].

the kinase-inhibition mechanism is also relevant to NAFLD biology because IKKe and TBK1 contribute to the inflammatory drivers of hepatic steatosis and steatohepatitis. rodent studies of amlexanox in NAFLD models have shown reductions in hepatic fat, inflammatory infiltrate, and fibrosis markers, with the same proposed cAMP-restoration mechanism in hepatocytes.

what does the human evidence show?

the most informative human study is a 24-week double-blind placebo-controlled Phase 2 trial of amlexanox in 42 obese patients with type 2 diabetes and NAFLD, reported by Oral and colleagues in 2017. the study did not meet its primary endpoint in the overall population but showed clinically meaningful reductions in HbA1c and hepatic fat in a responder subgroup characterized by a baseline inflammatory adipose-tissue signature.

Oral and colleagues randomized 42 adults with obesity, type 2 diabetes, and NAFLD to oral amlexanox or placebo for 24 weeks [4]. the primary endpoint was change in HbA1c. in the overall population the difference between arms did not reach significance. in a pre-specified responder analysis, however, the patients with the highest baseline expression of inflammatory adipose-tissue markers showed a clinically meaningful HbA1c reduction (approximately 0.5 percentage points beyond placebo) and reduced hepatic fat fraction on MRI spectroscopy. this is the proof-of-concept finding the Michigan group has built subsequent development around.

the natural read of the 2017 trial is that amlexanox engages its proposed mechanism in humans but does so most usefully in a defined subpopulation with an inflammatory metabolic phenotype, and that a future development program would need to enroll that subpopulation prospectively. the inflammation-stratified approach is in line with broader trends in metabolic-disease drug development that increasingly use biomarker-defined populations.

beyond the metabolic indication, amlexanox has been studied in small trials in pulmonary, oncology, and additional inflammatory contexts. none of these have reached registration-quality endpoints, and the metabolic indication remains the most-developed repurposing program. the original aphthous-ulcer use continues unchanged in clinical practice but at much smaller commercial scale than at original launch.

regulatory status

amlexanox 5% oral paste (Aphthasol) was FDA-approved in 1996 for treatment of aphthous ulcers. it has no other approved indication anywhere in the world. all metabolic-disease work is investigational, conducted under FDA Investigational New Drug authorizations, and is not part of routine clinical practice. there is no approved oral or systemic formulation of amlexanox in the US.

the historical regulatory path is unusual. amlexanox was first approved in Japan as an anti-allergic agent in 1987 and was carried forward in the US under the orphan-drug aphthous ulcer indication in 1996. the original US commercial sponsor exited the market and the brand passed through several owners before stabilizing as a generic prescription product. for the metabolic indication, the academic group at Michigan has pursued repurposing through formal IND-authorized trials rather than off-label prescribing.

the World Anti-Doping Agency does not currently list amlexanox by name on the prohibited list. because it is not anabolic, not a peptide hormone, and not in a hormone-modulator class, it does not fall under any of the relevant WADA categories. that may change if the metabolic-disease development program produces a marketed product with weight-loss labeling.

safety profile

the topical (oral paste) safety profile in the aphthous ulcer indication is well-characterized and benign: mild local irritation is the main adverse event. the oral systemic safety profile from the metabolic-disease trial was also well tolerated over 24 weeks, with no serious adverse events attributed to the drug. the long-term systemic-dose safety beyond six months has not been formally characterized.

the 2017 Oral and colleagues trial reported that systemic oral amlexanox over 24 weeks was generally well tolerated, with adverse-event rates similar between drug and placebo arms [4]. no signal of hepatotoxicity, hematological toxicity, or significant gastrointestinal toxicity emerged. these results are consistent with the long topical-use experience and with the rodent toxicology data.

the open safety questions are about chronic systemic exposure at doses sufficient for sustained IKKe and TBK1 inhibition. because these kinases sit in non-canonical NF-kB and innate-immunity pathways, there are theoretical concerns about long-term immune-function effects, infection susceptibility, and (in some animal models) effects on antiviral signaling. none of these have been observed in the existing human program, but the program is short and small [5].

where it fits in peptide therapy

amlexanox is not a peptide and does not "fit" in peptide therapy in a literal sense. it sits in this education set because it is one of the small-molecule mechanisms most often discussed alongside the GLP-1 incretin peptides as a candidate for obesity and metabolic-disease combination therapy. its mechanism (anti-inflammatory kinase inhibition restoring energy expenditure) is complementary to the appetite-suppressing GLP-1 mechanism rather than overlapping.

the natural conceptual comparison is the GLP-1 incretin family that includes semaglutide and tirzepatide. these are peptide therapeutics that drive weight loss largely by reducing food intake, with metabolic benefits downstream of caloric deficit and incretin-mediated glucose control. amlexanox is mechanistically orthogonal: it does not change appetite, it acts on energy expenditure and metabolic inflammation. the two mechanisms are theoretically complementary, which is why combination strategies have been discussed in the field.

a closer mechanistic comparison would be other small-molecule anti-inflammatory metabolic drug candidates, including salsalate (a non-acetylated salicylate that inhibits IKK-beta) and the BTK inhibitor evobrutinib in metabolic contexts. none of these has yet produced a registration-quality obesity or NAFLD outcome, and the field is increasingly biomarker-stratified to identify the inflammatory-phenotype subpopulations most likely to respond.

for a broader map of how obesity and NAFLD therapeutics are evolving and where the small-molecule and peptide approaches intersect, the underlying biology is covered in our free peptides and your body module, the GLP-1 family is compared in our GLP-1 comparison, and the FDA approval landscape is summarized in our peptide approval guide.